GeneSight Testing: Can it be Useful?

If you've had a difficult experience tapering a psychiatric medication, you may have wondered whether there is something about your individual biology that makes you more sensitive to the drug. You may also have heard about GeneSight or other pharmacogenetic (PGx) tests. These tests look at genetic variations that can influence how your body metabolizes certain medications. So an important question is: If my genes affect how I metabolize a psychiatric drug, could that affect my withdrawal? The short answer: Possibly—but GeneSight cannot predict your withdrawal. There is good evidence that genetic differences can affect how quickly some medications are metabolized and eliminated from the body. There is also emerging evidence that differences in drug clearance may be associated with antidepressant withdrawal. But that does not mean that GeneSight can tell you:

• whether you will experience withdrawal
• how severe your withdrawal will be
• how long your withdrawal will last
• whether you will develop protracted withdrawal
• how quickly you should taper
• what percentage reduction is appropriate for you

Those questions have not been validated by pharmacogenetic testing. What does GeneSight actually test? GeneSight Psychotropic analyzes several genes involved in how the body processes medications. Some of the most important enzymes include:

• CYP2D6
• CYP2C19
• CYP2B6
• CYP1A2
• CYP3A4

For certain medications, genetic differences can cause a person to metabolize a drug more slowly or more rapidly. This can potentially affect how much medication is present in the body at a particular dose. Why might metabolism matter during withdrawal? Consider two people taking the same medication at the same dose. One person may clear the medication relatively quickly. Another may clear it more slowly. Their blood levels and exposure to the medication may therefore be different. When the dose is reduced, the change in drug exposure may also differ between them. This is one reason pharmacokinetics may be relevant to withdrawal. Research has found that lower drug clearance may be associated with greater antidepressant withdrawal risk, although this does not prove that genetics alone determines withdrawal. In other words: Genes → metabolism → drug exposure → potentially different discontinuation experiences But there are many other factors involved. What about Effexor (venlafaxine)? This is particularly relevant to people taking venlafaxine (Effexor). Venlafaxine is substantially metabolized by the CYP2D6 enzyme. CYP2D6 converts venlafaxine into an active metabolite called desvenlafaxine. People can have genetically determined differences in CYP2D6 activity. They may be classified as:

• Poor metabolizers
• Intermediate metabolizers
• Normal metabolizers
• Ultrarapid metabolizers

These differences can affect the relationship between venlafaxine and its active metabolite. However, knowing your CYP2D6 status does not tell you how difficult your withdrawal will be. Even the clinical guidelines are cautious about using CYP2D6 results to make treatment decisions with venlafaxine because the relationship between genotype, drug concentrations, side effects, and clinical outcomes is complicated. Does being a "poor metabolizer" mean you'll have worse withdrawal? Not necessarily. This is an important misconception to avoid. A poor metabolizer may have greater exposure to a medication or its parent compound, depending on the drug. That could potentially affect treatment or discontinuation. But there is no validated rule saying: Poor metabolizer = severe withdrawal Likewise: Ultrarapid metabolizer = easy withdrawal is not established either. Real-world withdrawal is much more complicated. Your genes are only one piece of the puzzle Drug metabolism can also be affected by many other factors, including:

• other medications
• drug interactions
• smoking
• liver function
• kidney function
• age
• illness
• hormonal factors
• individual differences in absorption and elimination

And withdrawal itself involves more than drug metabolism. The nervous system can adapt to prolonged exposure to a psychiatric medication. Therefore, how quickly a drug leaves the bloodstream is not the same thing as how quickly the nervous system readjusts to its absence. This is a crucial distinction. GeneSight does NOT measure withdrawal sensitivity A GeneSight test cannot tell you whether you have:

• a "withdrawal-sensitive nervous system"
• increased susceptibility to protracted withdrawal
• a particular tapering requirement
• a specific percentage reduction you can tolerate
• a specific amount of time you need between reductions

There is currently no genetic test that can make those predictions reliably. Could GeneSight still be useful? Yes. Pharmacogenetic testing may provide useful information when someone has experienced unusual side effects, difficulty with multiple medications, or concerns about how they metabolize a particular drug. It may help a clinician think about:

• medication selection
• dosing
• potential drug-gene interactions
• possible differences in drug exposure
• adverse effects

But that is different from using the test to predict withdrawal. One important warning for people who are already tapering If you get a GeneSight result, don't automatically change your medication because of the result. A genetic result should be interpreted alongside your actual medication history and your clinical experience. If you are tapering and doing poorly, a result saying that you are a particular metabolizer does not necessarily mean that you should:

• reduce faster
• reduce slower
• increase your dose
• switch medications
• stop the medication

Your actual response to dose reductions remains extremely important. So, should you get GeneSight testing? There isn't a one-size-fits-all answer. It may be reasonable to discuss testing with a knowledgeable clinician if you're interested in understanding how your genetics could affect medication metabolism. But if your primary question is: "Why am I having such severe withdrawal?" GeneSight may provide one small piece of information, but it cannot provide the whole answer. The Bottom Line 🧬 Can genes affect how you metabolize a psychiatric drug? Yes. 💊 Can metabolism affect drug exposure? Yes. 📉 Could differences in drug clearance potentially affect withdrawal? Yes. Emerging research suggests that pharmacokinetic factors, including lower drug clearance, may be associated with greater withdrawal risk. 🧬 Can GeneSight predict whether you'll have withdrawal? No. 📊 Can GeneSight predict how severe your withdrawal will be? No. ⏳ Can it predict whether you'll develop protracted withdrawal? No. 📐 Can it tell you exactly how to taper? No. ❤️ Does a genetic result replace listening to your body's response to tapering? Absolutely not. One of the most important things to remember A genetic test can tell us something about how your body may process a drug. It cannot tell us everything about how your nervous system will respond when that drug is reduced or removed. Those are two different questions. Pharmacogenetic testing is an interesting and potentially useful tool—but when it comes to psychiatric-drug withdrawal, your genes are only one piece of a much larger puzzle.